# Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults

> **NCT01142362** · PHASE1 · COMPLETED · sponsor: **Inovio Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** VGX-3400X

## Key facts

- **NCT ID:** NCT01142362
- **Lead sponsor:** Inovio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01142362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01142362, "Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT01142362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*